# US Recombinant DNA Technology Market

> US Recombinant DNA Technology Market Research Report By Product (Medical, Non-Medical), By Component (Expression System, Cloning Vector), By Application (Food & Agriculture, Health & Disease) and By End User (Biotechnology Companies, Pharmaceuticals) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.43%
- **2024:** $ 111.47 Billion
- **2025:** $ 117.52 Billion
- **2035:** $ 199.4 Billion
- **Key Players:** Thermo Fisher Scientific (US), Agilent Technologies (US), Illumina (US), Merck KGaA (DE), GenScript Biotech Corporation (CN), Bio-Rad Laboratories (US), Qiagen (DE), Sangamo Therapeutics (US), Amgen (US)

**Report ID:** MRFR/LS/17968-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** May 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-recombinant-dna-technology-market-19515

---

## Market Summary

## **US Recombinant DNA Technology Market Overview**

As per MRFR analysis, the US Recombinant DNA Technology Market Size was estimated at 206.24 (USD Billion) in 2023. The US Recombinant DNA Technology Market Industry is expected to grow from 216.75(USD Billion) in 2024 to 393 (USD Billion) by 2035. The US Recombinant DNA Technology Market CAGR (growth rate) is expected to be around 5.559% during the forecast period (2025 - 2035).

### **Key US Recombinant DNA Technology Market Trends Highlighted**

The US Recombinant DNA Technology Market is shaped by several significant trends. A key market driver is the increasing demand for personalized medicine, as healthcare providers seek tailored treatments that cater to individual patient needs. The rise in chronic diseases and genetic disorders has also spurred interest in therapies developed through recombinant DNA technology, allowing for the creation of more effective treatments. 

The focus on biopharmaceuticals has heightened, with a growing number of biotech firms in the US dedicated to research and development in this field, supported by favorable government policies and funding that promote innovation and growth in biotechnology.Opportunities exist in leveraging advancements in synthetic biology and genome editing techniques, such as CRISPR, which promise to revolutionize the development of new therapies and vaccines. The ongoing COVID-19 pandemic has emphasized the critical importance of rapid vaccine development, leading to increased investments in recombinant DNA platforms that can facilitate this process.

Furthermore, collaborations between academic institutions, private companies, and government agencies are creating a more robust ecosystem for research and development, encouraging the commercialization of groundbreaking therapies and technologies. Trends in recent times also point towards a rising emphasis on ethical considerations and regulatory frameworks surrounding the use of recombinant DNA technology, particularly as public awareness and concern about genetic engineering grow.This has resulted in increased scrutiny and demand for transparency in research practices, which is crucial for gaining public trust and acceptance.

Overall, the US market is evolving, driven by unmet medical needs and technological advancements, paving the way for innovative solutions grounded in recombinant DNA technology.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Recombinant DNA Technology Market Drivers**

#### **Growing Demand for Personalized Medicine**

The increasing demand for personalized medicine is a significant driver for the US Recombinant DNA Technology Market Industry. As healthcare shifts towards more individualized treatment options, the market for recombinant DNA technology, which underpins many personalized therapies, is expected to grow.

The Precision Medicine Initiative, launched by the US government, aims to revolutionize the way diseases are treated by tailoring treatments to individual patient characteristics, which is projected to impact millions.According to the National Institutes of Health (NIH), a recent survey indicated that 69% of patients are willing to receive treatments based on their genetic information, indicating a strong market potential for technologies involved in genetic manipulation and therapy. The push for personalized medicine is driving robust Research and Development efforts within biotech organizations, such as Genentech and Amgen, which are heavily investing in gene therapy research.

#### **Rising Incidence of Genetic Disorders**

The increasing incidence of genetic disorders is another prominent driver of growth in the US Recombinant DNA Technology Market Industry. Genetic disorders, affecting a significant portion of the population, necessitate advanced treatment solutions rooted in recombinant DNA technology. The Centers for Disease Control and Prevention (CDC) indicates that approximately 1 in 33 babies are born with a genetic disorder, leading to a rising demand for therapies that can effectively address these conditions.This has prompted organizations such as the American Society of Human Genetics to advocate for research and funding in genetic therapies.

To address these increasing health challenges, companies like Vertex Pharmaceuticals are focusing on improving treatments for conditions like cystic fibrosis through innovative genetic approaches.

#### **Advancement in Biopharmaceuticals**

The advancement in biopharmaceuticals propelled by recombinant DNA technology serves as a crucial driver for the US Recombinant DNA Technology Market Industry. The number of biopharmaceuticals approved by the Food and Drug Administration (FDA) is on an upward trend, with approximately 60% of new drugs being biologics, including monoclonal antibodies and therapeutic proteins.

This growth is supported by the Biotechnology Innovation Organization, stating that biopharmaceutical sales reached over $300 billion in the US, representing a significant part of the pharmaceutical market.As established firms like Pfizer and Merck invest heavily in biologic drugs, the growth of the recombinant DNA technology industry is expected to follow suit, driven by ever-increasing innovation aimed at producing safer and more effective therapies.

#### **Supportive Regulatory Environment**

A supportive regulatory environment is facilitating growth within the US Recombinant DNA Technology Market Industry. The FDA's establishment of streamlined pathways for the approval of gene therapies, such as the Breakthrough Therapy Designation, has boosted development efforts. In the past few years, the FDA has approved numerous gene therapies, indicating a shift towards a more conducive regulatory framework.

According to the FDA, 2021 saw a record 50 new drug approvals, a notable portion of which were biologics, highlighting the regulatory support for innovative therapies.This environment encourages investment from top pharmaceutical companies like Bristol-Myers Squibb and Novartis, promoting greater involvement in recombinant DNA technology initiatives throughout the country.

### **US Recombinant DNA Technology Market Segment Insights**

#### **Recombinant DNA Technology Market Product Insights**

The US Recombinant DNA Technology Market has garnered significant attention due to its diverse range of products that cater to both medical and non-medical needs, showcasing the essential role of biotechnology in multiple sectors. In the medical arena, recombinant DNA technology plays a crucial part in the development of innovative therapies, vaccines, and diagnostic tools, contributing to advancements in healthcare. The escalating prevalence of chronic diseases, coupled with an aging population, is driving the demand for effective medical products, making this segment vital for public health in the US.

Moreover, with regulatory agencies like the Food and Drug Administration (FDA) supporting advancements in biotech, the medical segment continues to experience an influx of investment and Research and Development efforts, further solidifying its importance in shaping future healthcare solutions.

On the other hand, the non-medical applications of recombinant DNA technology make significant inroads into sectors such as agriculture, industrial biotechnology, and environmental management. The agricultural sector, for example, leverages genetic engineering to enhance crop yield, disease resistance, and pest tolerance, providing a pathway towards food security and sustainability in the US. This aspect not only promises economic benefits but also aligns with environmental conservation efforts by reducing the reliance on chemical pesticides and fertilizers. This synergy reinforces the significance of non-medical products derived from recombinant DNA technology, catering to both commercial and ecological interests.

The balance between medical and non-medical applications underscores the broad impact of the US Recombinant DNA Technology Market, presenting extensive opportunities for growth. The evolution of these product segments reflects ongoing advancements in technology and a deeper understanding of biological systems. Key market players are continuously exploring innovative solutions, leading to a rapid expansion in the commercial viability of recombinant products.

Overall, the intersection of medical and non-medical needs highlights a thriving biotechnology landscape in the US, attracting investments and propelling further developments across various industries, standing as a testament to the adaptability and relevance of recombinant DNA technology in contemporary society. The potential for breakthroughs in both sectors persists, indicating a promising trajectory for the industry in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Recombinant DNA Technology Market Component Insights**

The Component segment of the US Recombinant DNA Technology Market plays a crucial role in advancing genetic engineering and biopharmaceutical development. This segment includes essential components such as Expression Systems and Cloning Vectors, which are vital for modifying and producing genetic material efficiently. Expression Systems, which facilitate the generation of recombinant proteins, significantly streamline the production process in industries including pharmaceuticals and agriculture. This has led to a rise in their utilization, primarily due to the increasing demand for monoclonal antibodies and therapeutic proteins which require sophisticated expression platforms.

Cloning Vectors are equally significant as they enable the insertion, replication, and manipulation of DNA fragments in host organisms, promoting innovations in genetic research and biotechnology applications. The growing emphasis on personalized medicine and advanced therapies in the US has driven the need for reliable cloning technologies, which contributes to the segment’s prominence in the market. Additionally, favorable government policies related to biotechnology, coupled with substantial investments in Research and Development, support the growth of these components, emphasizing their importance in shaping the US Recombinant DNA Technology Market landscape.

#### **Recombinant DNA Technology Market Application Insights**

The US Recombinant DNA Technology Market primarily focuses on the Application segment, which plays a critical role in driving advancements across various industries. This segment encompasses key areas such as Food and Agriculture and Health and Disease, reflecting the broad scope and influence of recombinant DNA technology.

In the Food and Agriculture sector, this technology is pivotal for developing genetically modified organisms that enhance crop yields and resistance to pests and diseases, addressing food security concerns in a growing population.Meanwhile, the Health and Disease segment emphasizes the technology's vital contribution to the development of novel therapies and vaccines, significantly impacting public health and disease management. 

The increasing importance of personalized medicine is notable, as recombinant DNA technology paves the way for targeted treatments that cater to individual patient needs. As a result, these applications are expected to shape the future landscape of biotechnology significantly.

The market demonstrates a robust growth trend fueled by factors such as rising R&D investments and supportive government policies aimed at innovation and public health improvement.The US is recognized as a key player in life sciences, further enhancing the significance of the Application segment within the overall US Recombinant DNA Technology Market due to its advanced research infrastructure and strong industry collaboration.

#### **Recombinant DNA Technology Market End User Insights**

The US Recombinant DNA Technology Market is significantly driven by its end users, primarily focusing on Biotechnology Companies and Pharmaceuticals. The biotechnology sector plays a crucial role in advancing research and development, leveraging recombinant DNA technology to produce innovative therapies and diagnostics that address disease management and prevention. Pharmaceuticals, on the other hand, harness this technology to facilitate the creation of biologics and vaccines, which have become vital in combating various health challenges, including emerging infectious diseases.

Given the increasing demand for personalized medicine and biologically derived treatments, these end users are poised to contribute strategically to market growth. The integration of advanced genetic engineering techniques has enabled these sectors to develop drugs that are more effective, ultimately influencing market dynamics.

As organizations continue to invest in research initiatives and clinical trials, the importance of these end users is magnified, making them significant players in the evolution of the US Recombinant DNA Technology Market landscape.Their ongoing collaboration and innovation not only enhance healthcare outcomes but also stimulate economic progress within the biotechnology and pharmaceutical industries, leading to a robust market ecosystem.

### **US Recombinant DNA Technology Market Key Players and Competitive Insights**

The US Recombinant DNA Technology Market is characterized by rapid advancements and high levels of competition among key players that are continuously innovating to gain market share. The market is driven by the increasing demand for genetic engineering applications across various sectors, including pharmaceuticals, agriculture, and biotechnology. As the market evolves, companies are investing heavily in research and development to enhance their product offerings and improve their technological capabilities. The competitive landscape is marked by strategic collaborations, partnerships, and mergers that aim to bolster capabilities and expand market reach.

This dynamic environment is also influenced by regulatory frameworks and ethical considerations, which can significantly impact market operations.

#### Illumina

Illumina has established a strong presence in the US Recombinant DNA Technology Market by being at the forefront of next-generation sequencing and genomics. The company has gained recognition for its innovative products that cater to a broad range of applications, including genomic research, drug discovery, and personalized medicine. Illumina's strengths lie in its commitment to continuous innovation and the development of advanced sequencing technologies, which have significantly enhanced the accuracy and efficiency of DNA analysis.

By collaborating with research institutions and healthcare providers, Illumina has successfully expanded its market reach and user base in the United States, establishing itself as a trusted partner in the field of genomics.

#### Genentech

Genentech is a notable player in the US Recombinant DNA Technology Market, particularly known for its contributions to biopharmaceuticals and innovative therapies. The company's core offerings include a diverse portfolio of key biopharmaceutical products that address critical medical needs across areas such as oncology, immunology, and neuroscience. Genentech's innovative approach to drug development has led to significant advancements in personalized medicine, bolstered by a robust pipeline of biosimilars and therapeutics. 

The company has solidified its market presence through strategic mergers and acquisitions, further strengthening its capabilities and expanding its product range. Genentech's strong emphasis on research and development, along with its established relationships in the healthcare ecosystem, positions it as a pivotal player in the US Recombinant DNA Technology Market, consistently contributing to breakthroughs in medical science.

#### **Key Companies in the US Recombinant DNA Technology Market Include**

Illumina [Genentech](https://www.gene.com/stories/biotech-basics) Astrazeneca Novartis Zymeworks Gilead Sciences Regeneron Pharmaceuticals Sangamo Therapeutics Moderna CRISPR Therapeutics Agenus Amgen Biogen Vertex Pharmaceuticals

### **US Recombinant DNA Technology Market Industry Developments**

Recent developments in the US Recombinant DNA Technology Market indicate significant advancements and activities among leading companies. Illumina has made strides in genomic technologies, focusing on innovations in sequencing and array platforms, while Gilead Sciences continues to enhance its portfolio through gene editing initiatives. In October 2023, Astrazeneca announced plans to expand its recombinant DNA capabilities to better address patient needs. Notably, in June 2023, Moderna and CRISPR Therapeutics announced a collaboration aimed at advancing genetic medicines, marking a significant step in the field. 

In terms of mergers and acquisitions, Genentech's acquisition by Roche has continued to influence market dynamics since its announcement in early 2021, strengthening their position in the recombinant DNA landscape. Vertex Pharmaceuticals reported a strong market valuation growth, driven by its transformative therapies in cystic fibrosis and ongoing Research and Development efforts in gene editing. Over the last two to three years, the market has seen a steady shift towards personalized medicine, aligning with regulatory support from the US FDA to expedite gene therapies and biopharmaceuticals, indicating an optimistic future for the recombinant DNA sector in the US.

### **US Recombinant DNA Technology Market Segmentation Insights**

#### **Recombinant DNA Technology Market Product Outlook**

Medical Non-Medical

#### **Recombinant DNA Technology Market Component Outlook**

Expression System Cloning Vector

#### **Recombinant DNA Technology Market Application Outlook**

Food & Agriculture Health & Disease

#### **Recombinant DNA Technology Market End User Outlook**

Biotechnology Companies Pharmaceuticals

## Market Drivers

### Growing Awareness of Genetic Disorders

The recombinant dna-technology market is also driven by the growing awareness of genetic disorders among the public and healthcare professionals. As more individuals become informed about genetic conditions, there is an increasing demand for diagnostic tools and treatments that utilize recombinant dna technologies. This awareness is leading to a rise in genetic testing services, which are projected to grow by 15% annually through 2025. Consequently, the recombinant dna-technology market is poised to benefit from this trend, as healthcare providers seek innovative solutions to address genetic disorders. The integration of these technologies into clinical practice is likely to enhance patient outcomes and drive market growth.

### Expansion of Agricultural Biotechnology

The recombinant dna-technology market is experiencing growth due to the expansion of agricultural biotechnology. As the global population continues to rise, there is an urgent need for sustainable agricultural practices that can increase crop yields and resilience. The use of recombinant dna technologies in developing genetically modified crops is becoming increasingly prevalent. In 2025, the market for agricultural biotechnology is expected to reach $8 billion, reflecting a growing acceptance of GMOs among consumers and farmers alike. This trend is likely to enhance the recombinant dna-technology market, as innovations in crop genetics lead to improved food security and environmental sustainability.

### Rising Demand for Personalized Medicine

The recombinant dna-technology market is significantly influenced by the rising demand for personalized medicine. As healthcare shifts towards tailored treatments, the need for genetic testing and therapies that cater to individual genetic profiles is increasing. This trend is evident in the biopharmaceutical sector, where companies are investing heavily in developing targeted therapies based on genetic information. In 2025, the market for personalized medicine is expected to grow at a CAGR of over 10%, indicating a robust opportunity for recombinant dna technologies. The ability to create specific treatments for conditions such as cancer and rare genetic disorders is driving this demand, thereby enhancing the overall landscape of the recombinant dna-technology market.

### Increased Funding for Biotechnology Research

The recombinant dna-technology market is benefiting from increased funding for biotechnology research. Government initiatives and private investments are fueling innovation in genetic research and development. In the US, funding for biotechnology research has seen a substantial rise, with federal grants and venture capital investments reaching over $5 billion in 2025. This influx of capital is enabling researchers to explore new applications of recombinant dna technologies, from drug development to agricultural enhancements. As research progresses, the recombinant dna-technology market is likely to expand, with new products and solutions emerging to meet the evolving needs of various industries.

### Advancements in Genetic Engineering Techniques

The recombinant dna-technology market is experiencing a surge due to advancements in genetic engineering techniques. Innovations such as CRISPR and TALEN have revolutionized the ability to edit genes with precision. These technologies enable researchers to develop new therapies for genetic disorders, enhancing the market's growth potential. In 2025, the market is projected to reach approximately $10 billion, driven by the increasing application of these techniques in pharmaceuticals and agriculture. The ability to create genetically modified organisms (GMOs) that are resistant to diseases and pests is particularly appealing to agricultural sectors, thereby expanding the recombinant dna-technology market. As these techniques become more refined, their adoption across various industries is likely to accelerate, further propelling market growth.

## Future Outlook

The [Recombinant DNA Technology Market](https://www.marketresearchfuture.com/reports/recombinant-dna-technology-market-5845) is projected to grow at a 5.43% CAGR from 2025 to 2035, driven by advancements in biotechnology, increasing R&D investments, and rising demand for genetic therapies.

**New opportunities:**

- Development of personalized gene therapies targeting rare diseases. Expansion of CRISPR-based solutions for agricultural biotechnology. Investment in automated laboratory systems for enhanced research efficiency.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Product: Medical (Largest) vs. Non-Medical (Fastest-Growing)

The US recombinant dna-technology market demonstrates a clear preference for the Medical segment, which captures the majority share due to its wide-ranging applications in healthcare, including diagnostics and therapeutics. This segment benefits from substantial investments in research and development, leading to innovative solutions that improve patient outcomes. Conversely, the Non-Medical segment, while smaller in market share, is rapidly gaining traction as biotechnological advancements facilitate its use in agriculture, environmental solutions, and industrial applications. Growth trends indicate that the Medical segment will continue to dominate, driven by aging populations and increasing incidences of chronic diseases demanding advanced treatment options. Meanwhile, the Non-Medical segment is emerging as a fast-growing area, propelled by the rise of bio-based products and sustainable practices. Enhanced awareness and regulatory support for biotechnological solutions further bolster growth in both segments as they evolve to meet diverse market needs.

Medical (Dominant) vs. Non-Medical (Emerging)

The Medical segment stands as the dominant force within the US recombinant dna-technology market, characterized by its deep integration into healthcare practices and substantial investment in biotech innovation. This segment not only includes therapeutics but also diagnostics, showcasing a spectrum of applications that enhance patient care and treatment efficacy. On the other hand, the Non-Medical segment is gaining momentum, emerging as a vital component of the market as it embraces technologies for agriculture and industrial applications. The increasing focus on sustainability and environmentally friendly products positions the Non-Medical segment for significant growth, making it a promising area for future exploration, innovation, and investment.

### By Component: Expression System (Largest) vs. Cloning Vector (Fastest-Growing)

The market share distribution within the component segment of recombinant dna-technology reveals that Expression Systems hold the largest share due to their critical role in protein production and the growing demand for biologics. Cloning Vectors, while smaller in share, are witnessing a significant rise as advancements in gene editing technologies promote their adoption across various applications. In terms of growth trends, the increasing focus on personalized medicine and biopharmaceuticals is driving the demand for Expression Systems, which are essential for producing therapeutic proteins. Conversely, Cloning Vectors are experiencing rapid growth, supported by innovations in cloning techniques and their emerging use in synthetic biology, which positions them as an essential tool for researchers and developers in the recombinant dna-technology landscape.

Component: Expression System (Dominant) vs. Cloning Vector (Emerging)

Expression Systems are characterized by their ability to efficiently produce proteins, making them dominant in the US recombinant dna-technology market. They are utilized in various applications, including drug production and vaccine development. The adoption of these systems is driven by their versatility and efficiency, along with advances in mammalian, bacterial, and yeast expression systems. In contrast, Cloning Vectors are emerging as a vital component, especially in genetic engineering and synthetic biology. Their fast growth is attributed to the increasing need for precise DNA manipulation and the rising popularity of CRISPR technology, enabling rapid advancements in genomic research and therapeutic developments.

### By Application: Health & Disease (Largest) vs. Food & Agriculture (Fastest-Growing)

In the US recombinant dna-technology market, the Application segment is primarily bifurcated into Health & Disease and Food & Agriculture. Health & Disease continues to hold the largest share due to its crucial role in developing therapeutics and vaccines. This segment's importance has surged as advancements in genomic research propel innovations, leading to its dominancy in both share and influence. Conversely, Food & Agriculture, while smaller currently, is emerging rapidly as consumers become more aware of sustainable practices and the benefits of genetically modified organisms, contributing to a shift in preferences and market dynamics. The growth trends within these segments are shaped by several key drivers. The Health & Disease segment sees increased funding and research efforts, particularly in precision medicine, which enhances patient care through targeted therapies. Meanwhile, Food & Agriculture is witnessing a transformation driven by technological advancements and the need to address food security challenges. Innovations in genetically engineered crops promise higher yields and resistance to pests and diseases, contributing to its fast growth trajectory in the market.

Health & Disease: Dominant vs. Food & Agriculture: Emerging

The Health & Disease segment is characterized by its extensive application in therapeutic development, particularly in gene therapies and personalized medicine. This dominance is fueled by increased investment in biopharmaceutical research and a growing recognition of the potential of recombinant techniques, which enhance the efficacy of treatment options. In contrast, the Food & Agriculture segment, while emergent, is rapidly gaining traction as it addresses modern agricultural challenges, focusing on sustainable practices and improved crop resilience. Innovations in this sector are pioneering high-yield and pest-resistant varieties, catering to the growing demand for food security. As consumer awareness rises, this segment is projected to grow more significantly, presenting opportunities for investment and development.

### By End User: Biotechnology Companies (Largest) vs. Pharmaceuticals (Fastest-Growing)

In the US recombinant dna-technology market, the end user segment is primarily dominated by biotechnology companies, which hold a significant share due to their extensive research and development activities. These companies leverage recombinant dna technology for various applications including therapeutic development and genetic engineering, resulting in a sturdy demand in the market. On the other hand, pharmaceuticals are increasingly adopting these technologies to enhance drug formulation and expand their product pipelines, making them a crucial segment that showcases growth potential. As the pharmaceutical sector experiences rapid advancements in biotechnology and personalized medicine, it is positioned as the fastest-growing segment within the US recombinant dna-technology market. This growth is driven by an increase in investments for research and development, favorable regulatory frameworks, and a rising need for innovative therapies. The collaborative efforts between pharmaceutical firms and biotech companies also contribute to enhanced product offerings and expedited market penetration, further propelling the growth of this segment.

Biotechnology Companies (Dominant) vs. Pharmaceuticals (Emerging)

The biotechnology companies segment is the dominant player in the US recombinant dna-technology market, characterized by their robust innovation capabilities and a strong emphasis on research and development. These companies utilize recombinant dna technology for diverse applications, ranging from genetic modification to vaccine development, making them pivotal in addressing modern healthcare challenges. Conversely, the pharmaceuticals segment, while emerging, showcases significant growth potential as traditional drug manufacturers integrate biotechnology solutions into their processes. This integration helps enhance drug efficacy and safety, leading to better therapeutic outcomes. Together, both segments are vital, with biotechnology companies leading the charge while pharmaceuticals rapidly adapt to harness recombinant dna technology.

## Competitive Benchmarking

The recombinant dna-technology market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on expanding applications in biotechnology and pharmaceuticals. Key players such as Thermo Fisher Scientific (US), Illumina (US), and Merck KGaA (DE) are at the forefront, leveraging their technological capabilities to enhance product offerings and market reach. Thermo Fisher Scientific (US) emphasizes innovation through continuous investment in R&D, while Illumina (US) focuses on expanding its genomic sequencing technologies. Merck KGaA (DE) adopts a strategy of strategic acquisitions to bolster its portfolio, thereby shaping a competitive environment that is increasingly collaborative and technology-driven.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with a mix of established players and emerging companies. This fragmentation allows for diverse approaches to market entry and growth, with key players exerting considerable influence through their established reputations and technological advancements.
In October Thermo Fisher Scientific (US) announced the launch of a new line of CRISPR-based gene editing tools aimed at accelerating research in genetic therapies. This strategic move is likely to enhance their competitive edge by addressing the growing demand for precise and efficient gene editing solutions, thereby positioning the company as a leader in this rapidly evolving segment.
In September Illumina (US) unveiled a partnership with a leading pharmaceutical company to develop personalized medicine solutions utilizing its advanced sequencing technologies. This collaboration underscores Illumina's commitment to integrating genomic data into clinical applications, potentially revolutionizing patient care and solidifying its market position.
In August Merck KGaA (DE) completed the acquisition of a biotech firm specializing in recombinant protein production. This acquisition is strategically significant as it expands Merck's capabilities in biopharmaceutical manufacturing, allowing for enhanced product development and a stronger foothold in the recombinant dna-technology market.
As of November current trends in the recombinant dna-technology market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on technological advancements and supply chain reliability, rather than solely on price. This shift indicates a transformative phase where innovation and strategic partnerships will be paramount in defining success in the recombinant dna-technology market.

## Recent News & Developments

Recent developments in the US Recombinant DNA Technology Market indicate significant advancements and activities among leading companies. Illumina has made strides in genomic technologies, focusing on innovations in sequencing and array platforms, while Gilead Sciences continues to enhance its portfolio through gene editing initiatives. In October 2023, Astrazeneca announced plans to expand its recombinant DNA capabilities to better address patient needs. Notably, in June 2023, Moderna and CRISPR Therapeutics announced a collaboration aimed at advancing genetic medicines, marking a significant step in the field. 

In terms of mergers and acquisitions, Genentech's acquisition by Roche has continued to influence market dynamics since its announcement in early 2021, strengthening their position in the recombinant DNA landscape. Vertex Pharmaceuticals reported a strong market valuation growth, driven by its transformative therapies in cystic fibrosis and ongoing Research and Development efforts in gene editing. Over the last two to three years, the market has seen a steady shift towards personalized medicine, aligning with regulatory support from the US FDA to expedite gene therapies and biopharmaceuticals, indicating an optimistic future for the recombinant DNA sector in the US.

## Report Scope

| MARKET SIZE 2024 | 111.47(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 117.52(USD Billion) |
| MARKET SIZE 2035 | 199.4(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.43% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Agilent Technologies (US), Illumina (US), Merck KGaA (DE), GenScript Biotech Corporation (CN), Bio-Rad Laboratories (US), Qiagen (DE), Sangamo Therapeutics (US), Amgen (US) |
| Segments Covered | Product, Component, Application, End User |
| Key Market Opportunities | Advancements in gene editing technologies drive innovation in the recombinant dna-technology market. |
| Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the recombinant DNA-technology market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US recombinant dna-technology market in 2024?**
A: The market valuation was $111.47 Billion in 2024.

**Q: What is the projected market valuation for the US recombinant dna-technology market by 2035?**
A: The projected valuation for 2035 is $199.4 Billion.

**Q: What is the expected CAGR for the US recombinant dna-technology market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 5.43%.

**Q: Which segments contributed to the US recombinant dna-technology market in 2024?**
A: In 2024, the Medical segment contributed $66.88 Billion, while the Non-Medical segment contributed $44.59 Billion.

**Q: What are the key components of the US recombinant dna-technology market?**
A: Key components include Expression Systems, valued at $66.88 Billion, and Cloning Vectors, valued at $44.59 Billion in 2024.

**Q: Which applications are driving growth in the US recombinant dna-technology market?**
A: The Health & Disease application was valued at $66.47 Billion, while Food & Agriculture was valued at $45.0 Billion in 2024.

**Q: Who are the leading players in the US recombinant dna-technology market?**
A: Key players include Thermo Fisher Scientific, Agilent Technologies, Illumina, and Merck KGaA.

**Q: What was the valuation of the biotechnology companies segment in 2024?**
A: The biotechnology companies segment was valued at $66.88 Billion in 2024.

**Q: What is the projected growth for the Non-Medical segment by 2035?**
A: The Non-Medical segment is projected to grow to $79.4 Billion by 2035.

**Q: How does the US recombinant dna-technology market compare between 2024 and 2035?**
A: The market is expected to grow from $111.47 Billion in 2024 to $199.4 Billion by 2035, indicating robust growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-recombinant-dna-technology-market-19515*